DailyIQ
|
Sector:HealthcareAll sectors
Last updatedUpdating…

PFE·Pfizer Inc.

$29.42
+0.21 (+0.72%)
After Hours
High
$29.88
Open
$29.60
Market Cap
167.94B
52W High
$29.57
Low
$29.25
P. Close
$29.42
P/E
38.76
52W Low
$23.62
Fwd P/E
10.06
DailyIQ Est.
$29.36
Inst. Ownership
31.6%
Short Interest
2.55%
Days to Cover
4.4
Div. Yield
5.86%
Next Ex-Div
~Oct 23
Div. Growth
16+ yrs
NewEarnings release, scored · filed Aug 4, 2026Guidance raised · tone +0.9 vs prior release · 150 lines scoredSee the breakdown
Technical Score (1D)
54
NEUTRAL
News Sentiment
62
BULLISH
On Oct 13, Pfizer announced that its dividend would remain at a 6.3% yield, citing a strong free‑cash‑flow position that covered the payout with an 89% ratio and a 2.5% annual dividend growth rate from fiscal 2020 to 2025. That same day, the company entered a research collaboration and licensing agreement with Enodia Therapeutics, gaining access to Enodia’s proprietary Sec61 inhibitor platform and taking responsibility for the clinical, regulatory, and commercial development of Sec61‑targeting small‑molecule drugs, thereby adding a new discovery track to its pipeline. Also on Oct 13, analysts reported that Pfizer’s trailing earnings were $0.77 per share while its forward estimate was $2.90, noting that the 6% dividend yield exceeded twice the reported earnings and raising concerns about the sustainability of the dividend policy. The dividend announcement reinforced investor confidence in Pfizer’s cash‑generation capability and dividend policy, while the partnership with Enodia was highlighted as a strategic expansion of the company’s therapeutic portfolio. Analysts expressed caution regarding the high payout relative to earnings, suggesting that the dividend strategy could be a point of concern for investors.
LOW TARGET
$25 -15.1%
3 analysts
MEAN TARGET
$29 -0.6%
21 analysts
HIGH TARGET
$36 +22.3%
12 analysts
PRICE RANGE
$25.00 - $36.00
SB / B / H / S / SS
6/8/20/1/1
DAILYIQ EST.
$29.36 (-0.3%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
pfizer.com
Symbol
PFE
Description
Pfizer is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and distribution of medicines and vaccines. Their diverse portfolio addresses a range of therapeutic areas, including cardiovascular health, infectious diseases, and oncology, with notable brands like Eliquis, Comirnaty, and Paxlovid. Pfizer's value proposition lies in its commitment to addressing unmet medical needs through innovative treatments, including biosimilars and therapies for chronic and rare diseases. The company strategically collaborates with other pharmaceutical entities, such as Bristol-Myers Squibb and BioNTech SE, to enhance its research and development capabilities. With a history dating back to 1849, Pfizer continues to serve a wide network of healthcare providers and patients worldwide.
Bought (1Y)
114,863 shares
$3.0M
Sold (1Y)
5,278 shares
$135K
BOURLA ALBERTChairman & CEO
Award/Grant71 shares2026-10-13
BOURLA ALBERTChairman & CEO
Award/Grant21 shares2026-09-30
Taraporevala Cyrus-
Award/Grant1,307.987 shares2026-09-25
SMITH JAMES C-
Award/Grant1,569.585 shares2026-09-25
Quincey James-
Award/Grant1,351.587 shares2026-09-25
View full insider trading history →
65/ 100
Bullish
Overall: Bullish
✕Revenue declining year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
12.4%
Revenue CAGR
1.4%
Current Ratio
1.16x
Debt / Equity
0.75x
Return on Equity
9.0%
View full financials →
Earnings Summary
Pfizer is a global biopharmaceutical company that develops, manufactures, and distributes medicines and vaccines across cardiovascular, infectious disease, and oncology therapeutic areas, leveraging collaborations such as those with Bristol‑Myers Squibb and BioNTech to enhance its R&D pipeline. The company operates within the broader drug manufacturers sector, where innovation and patent lifecycles drive performance. In the most recent four quarters, Pfizer’s earnings per share (EPS) have consistently exceeded analyst expectations: Q4 2024 EPS of $0.63 beat the $0.46 estimate, Q1 2025 EPS of $0.92 beat the $0.67 estimate, Q2 2025 EPS of $0.78 beat the $0.57 estimate, and Q3 2025 EPS of $0.87 beat the $0.63 estimate. Revenue has trended upward, with Q4 2024 revenue of $17.76 billion, Q1 2025 $13.71 billion, Q2 2025 $14.65 billion, and Q3 2025 $16.65 billion, reflecting a steady 8–12% growth cycle and a rebound from the lower Q1 2025 figure. The pattern of EPS beats across four consecutive quarters underscores a robust earnings trajectory, while revenue growth has remained positive even when EPS growth decelerated slightly in Q4 2025 and Q1 2026. Historically, Pfizer has maintained a YoY revenue growth rate of roughly 5–7% over the past five years, with EPS growth consistently outpacing revenue growth, indicating efficient cost management and pricing power. Recent news highlights a strategic partnership with Enodia Therapeutics announced on October 13, which adds a new discovery track focused on Sec61‑targeting small‑molecule drugs, potentially diversifying Pfizer’s pipeline beyond its flagship biologics. The company also reaffirmed a 6.3% dividend yield, citing strong free‑cash‑flow coverage, though analysts noted concerns about dividend sustainability relative to earnings.

EPS

EstBeatMiss
$0.53$0.63$0.72$0.82$0.91Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.73 - -
Q2'26$0.69$0.77+11.4%
Q1'26$0.72$0.75+3.9%
Q4'25$0.58$0.66+14.3%
Q3'25$0.63$0.87+37.4%
Q2'25$0.57$0.78+35.9%

Revenue

EstBeatMiss
$13.2B$14.5B$15.7B$16.9B$18.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$16.1B - -
Q2'26$14.5B$15.0B+3.3%
Q1'26$13.8B$14.5B+4.7%
Q4'25$17.1B$17.6B+2.6%
Q3'25 - $16.7B -
Q2'25 - $14.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PFE Stock Snapshot

NEUTRAL54/100
$29.35−$0.07 (0.2%)
Market cap
167.94B
P/E ratio
38.8
Day range
$29.25 – $29.88
News sentiment
62/100 · Bullish
Analyst target
$29.26 (-0.3%)
Consensus
Hold · 36 analysts
52-week range+24.3% off low · -0.7% from high
$23.62$29.57
Price $29.35 DailyIQ Est. $29.36

The setup on Pfizer Inc. is patient: consolidation, not accumulation or distribution. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into PFE?

RICH

At today's price, Pfizer Inc. needs to grow free cash flow about 4.7% a year for the next 10 years to justify its valuation at a 6.93% cost of capital. Over its actual history it has compounded free cash flow at -1.5% a year, so the market is asking for 6.3 percentage points above its own delivered rate. On that basis PFE looks priced above what its own growth record supports.

Implied FCF growth
4.7%
Historical FCF CAGR
-1.5%
Growth gap
+6.3 pts
Verdict
RICH
Discount rate (WACC)
6.93%
Beta
0.60

Behaviour On Record

What PFE's own history says about today's numbers

Realized volatility (21d)
16.5% 37th pct
Below its peak
-51.8%
vs 200-day average
+11.0%
Up days (1y)
52%

Pfizer Inc. is currently running 16.5% annualised volatility over the last 21 sessions. Measured against PFE's own 13 years of daily returns rather than a market-wide average, that is the 37th percentile — on the quiet side for this stock, against a typical reading of 18.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

PFE is trading -51.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -20.2%, and the deepest was -48.8% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +11.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year PFE closed higher on 52% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 14 years of records, PFE finished the month higher 7 of 14 times, with a median return of +0.4% and an average of -0.2%. Its strongest month historically has been November at +3.3% on average, its weakest January at -3.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: PFE has opened more than 2% away from the prior close in 24 of 3,268 sessions (0.7% of the time), with the largest gaps running +4.3% and -3.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, PFE moved an average of 1.8% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.7% and a largest of +3.8%.

All figures computed from 3,269 daily closes between 2013-10-16 and 2026-10-15, split-adjusted, recomputed daily. Percentiles are against PFE's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of PFE's sector?

Pfizer Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#1 of 12
Sector state
Leading
Sector rotation score
100

Options Market

What is the options market pricing for PFE?

CallsPuts

For Pfizer Inc.'s nearest expiry (2026-10-16, 1 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.39), with at-the-money implied volatility around 24.0%. The options market is pricing roughly a ±1.3% move by that expiry — a range of about $29.28–$30.06.

Put/call ratio (2026-10-16)
0.39
ATM implied volatility
24.0%
Total open interest
234,408
Expected move by 2026-10-16
±1.3% ($29.28–$30.06)

Analyst Rating Changes

Are analysts turning bullish or bearish on PFE?

JP Morgan most recently reiterated its rating on Pfizer Inc. to Neutral on Oct 9, 2026 with a price target of $30 (from $28). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
JP Morgan — Neutral
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 9, 2026JP MorganMaintainedNeutral$28 → $30
Oct 8, 2026Cantor FitzgeraldMaintainedNeutral$27 → $28
Oct 6, 2026ScotiabankMaintainedSector Outperform$30 → $33
Sep 10, 2026HSBCMaintainedHold$28 → $30
Aug 7, 2026GuggenheimMaintainedBuy$35 → $31
Jul 13, 2026BMO CapitalMaintainedOutperform$34 → $30
Jul 13, 2026GuggenheimMaintainedBuy$36 → $35
Jul 10, 2026B of A SecuritiesMaintainedNeutral$27 → $26
Jul 8, 2026JP MorganMaintainedNeutral$30 → $28
Jul 6, 2026Cantor FitzgeraldReiteratedNeutral$27
Jul 6, 2026HSBCDowngradeBuy → Hold$32 → $28
Jun 10, 2026RBC CapitalUpgradeUnderperform → Sector Perform$25

Earnings Release, Scored

What did Pfizer Inc.'s latest earnings release say?

Filed Aug 4, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone70.6/ 100+0.9 vs prior release
Hedging words1.02per 100 words+0.73 vs prior release
Tone, last 2 releasesScale 50–76

Most important lines

  1. 1

    NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance (2) for Adjusted (3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction.

    Guidance raisedNew this quarter
  2. 2

    ■ Announces Additional Anticipated Productivity Enhancement Savings of $2.5 Billion (5) Associated with Ongoing Initiatives, Expected to be Realized From 2027 Through 2029

    Guidance raisedNew this quarter
  3. 3

    ■ Raises Full-Year 2026 Revenue Guidance (2) by $500 Million at the Midpoint to a Range of $60.5 to $62.5 Billion

    Guidance raisedNew this quarter

Scores describe the release's wording. They are not a forecast.

Read all 150 scored lines →

Peers & ETF holders

PFE peers & ETF holders

Drug Manufacturers - GeneralMarket cap · today

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

62/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Pfizer reported that its dividend will be maintained at a 6.3% yield, following a strong free‑cash‑flow position that covered the payout with an 89% ratio. The company’s dividend growth of 2.5% per year from fiscal 2020 to 2025 supports the sustainability of the payout. In contrast, Enbridge’s higher debt load and slightly lower yield of 6.0% make Pfizer a more attractive dividend choice for long‑term investors. The announcement reinforced investor confidence in Pfizer’s cash‑generation capability and dividend policy.
What did this article say?
Pfizer entered a research collaboration and licensing agreement with Enodia Therapeutics to develop Sec61-targeting small‑molecule drugs. Enodia provided access to its proprietary Sec61 inhibitor platform, while Pfizer assumed responsibility for clinical, regulatory, and commercial development. The partnership is designed to apply Sec61‑directed molecules across multiple disease areas, thereby adding a new discovery track to Pfizer’s pipeline.
What did this article say?
Pfizer Inc. reported trailing earnings of $0.77 per share while maintaining a forward estimate of $2.90, yet the company continues to pay a 6% dividend yield. The dividend payout exceeds twice the reported earnings, signaling potential over‑distribution. Analysts flagged the gap as a warning that the dividend may not be sustainable in the near term. The stock’s recent performance reflected modest gains, but the dividend strategy remains a point of concern for investors. The situation highlights the risk of high payouts when earnings are weak.
What did this article say?
Pfizer Inc. has underperformed shareholders over the past year, leaving the stock trading at roughly 9.6 times forward adjusted earnings based on its 2026 guidance. The company’s 2026 EPS midpoint is lower than the 2025 midpoint, indicating a projected earnings decline. Analysts note that a low multiple alone does not confirm undervaluation, as the market may be pricing in ongoing earnings pressure. The article highlights that several other healthcare stocks rank higher in hedge fund rankings, suggesting limited upside potential for Pfizer. Overall, the piece signals a modest negative outlook for the company’s valuation prospects.
What did this article say?
Pfizer’s GAAP payout ratio reached 226%, exceeding its adjusted earnings and raising concerns about dividend sustainability. The company was omitted from a list of top stocks to buy, indicating market skepticism. While free cash flow guidance remains above $21.5 billion, the high dividend yield is not fully supported by earnings or cash flow. Investors are cautioned that the dividend may become unsustainable if earnings and free cash flow fail to cover it.
What did this article say?
The article notes that Pfizer’s 6.1% dividend yield is appealing to income investors, yet the company faces significant patent expirations that could erode future earnings. It highlights that while cash flow currently supports the dividend, earnings have not yet matched the payout, raising concerns about sustainability. The piece advises diversifying across other pharma stocks to mitigate concentration risk.
What did this article say?
Pfizer is highlighted as a leading example of a large drugmaker employing artificial intelligence to expedite the discovery and design of new medicines. The company remains a major revenue generator, with 2024 sales projected at US$62.3 billion from its broad biopharma portfolio. The article notes that while AI adoption is growing in healthcare, Pfizer’s current use of the technology is primarily aimed at improving productivity rather than delivering immediate financial gains. The piece positions Pfizer as a useful benchmark for investors assessing the broader impact of AI on pharmaceutical productivity. No immediate guidance changes or material events are reported.
What did this article say?
Four Wall Street firms increased their Pfizer price targets between October 6 and 9, raising the consensus from roughly $28 to $30 while maintaining neutral ratings. JPMorgan, BofA, and Cantor Fitzgerald cited a Q3 preview and the MEVPRO‑1 prostate cancer trial as reasons for the modest lift. Scotiabank moved its target to $33 and upgraded to outperform, reflecting optimism about upcoming milestones. The consensus revenue outlook for 2029‑2030 rose by less than 0.3%, indicating limited impact on long‑term guidance.
What did this article say?
Pfizer achieved a 22.1% share price increase over the past year, largely driven by oncology developments such as the expanded use of Tukysa in HER2-positive metastatic breast cancer. Analysts question whether the current earnings level can justify the elevated stock price, comparing it to the Fair Ratio benchmark. The article highlights ongoing discussions among analysts about whether Pfizer’s valuation remains supported by its earnings trajectory.

Technical Analysis

Real-time indicators across multiple timeframes

54
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $45.13B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy541,346,1829.19%$13.48B2026-01-29
BlackRock, Inc.▲ Buy529,670,4338.99%$12.75B2026-08-07
Geode Capital Management, LLC▲ Buy135,275,7822.30%$3.25B2026-08-12
Fisher Asset Management, LLC▲ Buy109,067,2911.85%$2.63B2026-08-04
Morgan Stanley▲ Buy96,345,4521.64%$2.32B2026-08-13
Norges Bank▼ Sell61,505,5861.04%$1.48B2026-08-12
Northern Trust Corp▼ Sell59,084,5731.00%$1.42B2026-08-13
Goldman Sachs Group Inc▲ Buy52,991,8500.90%$1.28B2026-08-14
Bank of America Corp▼ Sell43,588,1090.74%$1.05B2026-08-14
Invesco Ltd.▲ Buy29,307,2090.50%$705.72M2026-08-14
Wellington Management Group LLP▼ Sell27,826,0780.47%$670.05M2026-08-14
JPMorgan Chase & Co▼ Sell23,010,2440.39%$560.76M2026-08-12
Capital World Investors▲ Buy22,218,1900.38%$535.01M2026-08-12
Wells Fargo & Company▲ Buy20,193,6750.34%$486.26M2026-08-14
Citigroup Inc▲ Buy19,228,1150.33%$463.01M2026-08-03
AQR Capital Management LLC▲ Buy18,557,8910.32%$445.02M2026-08-14
FMR LLC (Fidelity)▲ Buy15,397,2940.26%$370.77M2026-08-13
Neuberger Berman Group LLC▲ Buy10,281,6520.17%$247.74M2026-08-13
AllianceBernstein L.P.▼ Sell6,760,8680.11%$189.85M2026-08-14
Prudential Financial Inc▲ Buy7,718,5450.13%$185.86M2026-08-12
Susquehanna International Group, LLP▲ Buy6,547,2460.11%$157.66M2026-08-14
Citadel Advisors LLC▼ Sell6,191,1860.11%$149.08M2026-09-02
D. E. Shaw & Co., Inc.▼ Sell5,414,2970.09%$130.38M2026-08-14
Adage Capital Partners GP, L.L.C.▲ Buy3,801,3020.06%$91.54M2026-08-14
Janus Henderson Group plc▼ Sell3,223,7140.05%$90.51M2026-05-18
Q2 2026 flow:73.22M sh bought ($1.76B)53.34M sh sold ($1.29B)net +19.88M sh (+$475.68M)
View full institutional holdings history →
Congressional Trading Activity
25 disclosed trades · ~$630.0K est. traded value · 11 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Tommy TubervilleSenateAL▼ Sell$15K - $50K2026-06-082026-07-16
Alan ArmstrongSenateOK▼ Sell$50K - $100K2026-03-242026-07-21
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-03-132026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-02-102026-03-09
James French HillHouseAR02▼ Sell$100K - $250K2025-12-312026-01-23
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-12-192026-01-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-08-052025-09-12
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-162025-08-13
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-06-172026-01-13
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-06-032025-07-16
Ron WydenSenateOR▼ Sell$1K - $15K2025-06-032025-07-02
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-05-302025-06-06
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-05-152025-05-31
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-04-292025-05-06
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-112025-05-08
Rob BresnahanHousePA08▼ Sell$15K - $50K2025-04-082025-04-28
Gilbert CisnerosHouseCA31▼ Sell$15K - $50K2025-03-312025-04-07
Carol Devine MillerHouseWV01▼ Sell$15K - $50K2025-03-102026-08-13
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-032025-04-16
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-02-262025-03-06
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-02-252025-03-27
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-02-242025-03-09
View full congressional trading history →

Discover More

EXEL
Exelixis Inc.
$63.00
+0.27%
PODD
Insulet Corporation
$136.24
-1.85%
RGEN
Repligen Corporation
$184.17
+0.00%
TMO
Thermo Fisher Scientific Inc.
$700.00
+0.49%
DGX
Quest Diagnostics Incorporated
$239.15
+0.04%
ISRG
Intuitive Surgical, Inc.
$427.99
+0.03%
CORT
Corcept Therapeutics Incorporated
$113.37
+0.01%
TBXU
Direxion Daily Biotech Top 5 Bull 2X ETF
$39.68
+0.00%
XLV
Health Care Select Sector SPDR Fund
$177.30
+0.08%
MDT
Medtronic plc
$95.22
-0.26%